🔎 Trials Near Me

Avaleht › Burkitti lümfoom › Idaho

Burkitti lümfoom kliinilised uuringud osariigis Idaho

6 uuringut haiguse Burkitti lümfoom jaoks otsivad osalejaid osariigis Idaho.

Linnad osariigis Idaho

Ametlik uuringutekst (inglise keeles)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Saint Luke's Cancer Institute - Boise, Boise
VärbamineFaas 2
366 Days – 46 Years · Kõik sood · Uuendatud 2. okt 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • Saint Alphonsus Cancer Care Center-Boise, Boise
  • Saint Alphonsus Cancer Care Center-Caldwell, Caldwell
  • Kootenai Health - Coeur d'Alene, Coeur d'Alene
  • ja veel 3
VärbamineFaas 3
Vanused 18–39 · Kõik sood · Uuendatud 2. okt 2026 · NCT03150693

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • Saint Alphonsus Cancer Care Center-Nampa, Nampa
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 29. sept 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Saint Luke's Cancer Institute - Boise, Boise
VärbamineFaas 2
365 Days · Kõik sood · Uuendatud 25. sept 2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Saint Luke's Cancer Institute - Boise, Boise
VärbamineFaas 2
Vanused 1–30 · Kõik sood · Uuendatud 1. sept 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Saint Luke's Cancer Institute - Boise, Boise
VärbamineFaas 3
365 Days – 25 Years · Kõik sood · Uuendatud 25. aug 2026 · NCT03959085

Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.